Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
FTRE is expected to report earnings to rise 2,100.00% to 43 cents per share on August 18
Q2'25
Est.
$0.44
Q1'25
Missed
by $0.39
Q4'24
Missed
by $0.24
Q3'24
Missed
by $0.09
Q2'24
Missed
by $0.27
The last earnings report on May 12 showed earnings per share of 1 cents, missing the estimate of 40 cents. With 2.76M shares outstanding, the current market capitalization sits at 463.45M.